Scientists Identify A Tumor Suppressor Gene Implicated In Breast Cancer

July 21, 1997

Scientists at Oregon Health Sciences University in collaboration with a team from the University of California at Santa Cruz have discovered that abnormal expression of a tumor suppressor gene is implicated in breast cancer. Their work appears in the July 22, 1997 issue of the Proceedings of the National Academy of Sciences and details the action of a gene called WT1, which had been previously linked to kidney cancer in children.

"The WT1 gene normally prevents cell division by inhibiting the synthesis of growth factors that themselves trigger cell growth," explains Charles T. Roberts, Ph.D., professor of pediatrics at Oregon Health Sciences University and a senior author on the paper. "Loss of WT1 function in the kidney causes Wilms tumor, the most common childhood abdominal cancer. We reasoned that malfunction of this gene in the breast may also cause tumors. Because scientists have long suspected that certain growth factors play a role in breast tumor growth and WT1 regulates these same growth factors, we studied the activity of the WT1 gene in normal human breast tissue as compared to a large sample of breast cancers." Roberts and his colleagues Gary B. Silberstein, Ph.D., and Charles W. Daniel, Ph.D., of UC Santa Cruz discovered that the WT1 gene is active in normal breast tissue. Nearly 70 percent of breast cancer samples, on the other hand, showed altered WT1 gene activity. "Abnormal expressi! ! on of the WT1 gene may be one of the earliest steps in the development of breast tumors because it is seen in carcinoma 'in situ,' the very beginning stage of breast cancer," says Roberts.

While some breast tumors grow rapidly and are highly resistant to treatment, others can be either successfully treated or contained for decades. Surgery, chemotherapy, radiation and bone marrow transplantation are currently among the physician's arsenal of weapons. Adding to this arsenal, sophisticated future treatments are expected to use gene therapy to restore functional tumor suppressor genes and will depend on the discovery of promising therapeutic targets such as the WT1 gene.

"The story is complex," explains Roberts, "because it has been difficult to find a single molecular or genetic defect that is common to all of the various different forms of breast tumors. Finding abnormal WT1 activity in several types of breast cancer suggests that defects in WT1 action may underlie many forms of breast cancer."

In the complex microworld of the cell, the culprit gene or molecule underlying a disease may be influenced by surrounding molecular events. For example, while the absence of a functional WT1 gene is frequently seen in breast tumors, WT1 is curiously present in a highly malignant subset of advanced breast tumors. "These are called estrogen receptor-negative tumors," explains Roberts, "and though WT1 is present in these tumor cells, it may be dysfunctional. This may be because another well known tumor suppressor gene called p53 is found in these advanced tumors and p53 is known to interact with WT1 and may interfere with its normal function."

"Linking a dysfunctional WT1 tumor suppressor gene, which is present in a high proportion of breast cancers, with the potential over expression of growth factors that have the capacity to stimulate tumors, provides an exciting new pathway for the development of therapies to treat breast cancer," says Philip F. Smith, Ph.D., director of the neuroendocrinology program at the National Institute of Diabetes and Digestive and Kidney Diseases, which funded the research. "The role of hormones and growth factors in the development of breast cancer is a priority area of the NIDDK, and this discovery reinforces the importance of support for fundamental research into cell growth in opening new avenues to attack breast cancer and other hormone-responsive cancers."

Pinpointing the role of abnormal WT1 gene action in the development of breast tumors paves the way for designing strategies directed at restoring the function of the gene in various forms of breast cancer. The previously discovered breast cancer genes known as BRCA I and II play a role in hereditary forms of the disease, which comprise only 5 to 10 percent of all breast cancer cases. "The possible relationship between changes in the WT1 gene and mutations in the BRCA genes remains to be discovered," explains Roberts, who also serves as the director of research at Doernbecher Pediatric Research Laboratories located at OHSU.

Oregon Health & Science University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to